 |
Technical Support
(877) SEPAX-US, press 3  TechSupport@sepax-tech.com |
  |
| By Separation Mode | By Brand | By Sample Based Application | |
|
Size Exclusion Ion Exchange Hydrophobic Interaction Ion Exclusion Sub-2 UHPLC Purification Reversed Phase Mixed-mode Phase HILIC View All |
SEC-MALS Unix / Unix-C Zenix / Zenix-C SRT / SRT-C SRT-10 / SRT-10C Proteomix HIC / IEX Antibodix Carbomix Proteomix RP View All |
ADC Antibody Biosimilar Carbohydrate Cell Lysate DNA/RNA Fusion Protein Glycan Glycoprotein Heparin |
Insulin Membrane Protein Organic Acid PEG/PEGylated Protein Peptide Polymer Protein Vaccine/VLP Others |
How May We Help You?
How May We Help You?
How May We Help You?
Your question has been submitted.
We will respond back to you shortly.
We will respond back to you shortly.
How May We Help You?
Please fill out all required fields.
Samples
Sample: DNA/RNADNA/RNA Recommended products
Size Exclusion:
Zenix
Zenix-C
SRT
SRT-C
Preparative SEC
Ion Exchange: Proteomix Antibodix Reversed phase: Proteomix RP Bio-C4
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Application Note
Featured Application Notes
All Application Notes
| App ID | Title |
| PD1011 | Separation of Plasmid Isoforms using Anion Exchange Chromatography (AEX) | Ion ExchangeProteomixResolution@Method OptimizationUHPLC@HPLC@FPLC1
| ZZ1006 | Oligonucleotide Separation on SEC, IEX and RP Columns | Ion Exchange@Ion Exchange@Reversed Phase@Size Exclusion@Size Exclusion@Size ExclusionZenix@Proteomix@Zenix-C@Proteomix RPResolution@Method Optimization@Pore Size Selection@Packing Chemistry@Orthogonal MethodHPLC1
| SR1002 | Sepax Circular RNA Separation by SEC and RP Methods | Size ExclusionSRTSEC@Affinity@IEX@HIC@RP@Service@Size Exclusion@Reversed Phase@HPLCHPLC1
| LR2022021051 | Literature Reference: Liquid chromatography methods for the separation of short RNA oligonucleotides | IEXProteomixOligonucleotide Separation, Optimization,HPLC1
| Sepax_mRNA2022 | mRNA HPLC Analysis on SEC, RP, Affinity, and IEX | SECSRT@Proteomix RPmRNA SeparationHPLC1
| LR2022021086 | Literature Reference: A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems | SECZenixRNA SeparationUPLC1
| monomix-dt20 | Sepax Monomix dT20 Affinity Resin | SECSRTmRNA SeparationHPLC@FPLC1
| LR202202962 | Literature Reference: RNA Circularization Diminishes Immunogenicity and Can Extend Translation Duration In Vivo | Size ExclusionSRTSize Exclusion@RNA Separation on Wide Pore Column@Separation of RNAHPLC1
| LR2022021136 | Literature Reference: Design and application of circular RNAs with protein-sponge function | Size ExclusionSRTSize Exclusion@RNA Separation on Wide Pore Column@Separation of RNAHPLC1
| LR2022021128 | Literature Reference: Engineered circular ADAR-recruiting RNAs increase the efficiency and fidelity of RNA editing in vitro and in vivo | Size ExclusionSRTSize Exclusion@RNA Separation on Wide Pore Column@Separation of RNAHPLC1
| LR2022021104 | Literature Reference: Intratumoral Delivered Novel Circular mRNA Encoding Cytokines for Immune Modulation and Cancer Therapy | Size ExclusionSRTSize Exclusion@RNA Separation on Wide Pore Column@Separation of RNAFPLC1
| LR2022021101 | Literature Reference: RNA circles with minimized immunogenicity as potent PKR inhibitors | Size ExclusionSRTSize Exclusion@RNA Separation on Wide Pore Column@Separation of RNAHPLC1
| LR2022021052 | Literature Reference: Engineering circular RNA for potent and stable translation in eukaryotic cells | Size ExclusionSRTSize Exclusion@RNA Separation on Wide Pore Column@Separation of RNAHPLC1
| PD1009 | Separation of DNA by Proteomix RP Column | Reversed PhaseProteomix RPSeparation of DNAHPLC1
| PD1008 | Nucleotide Analysis on Proteomix SAX Column | Ion ExchangeProteomixNucleotide AnalysisHPLC1
| PD1007 | mRNA Separation on SEC and RP | Size Exclusion@Reversed PhaseSRT@ProteomixmRNA SeparationHPLC1
| SR1001 | Separation of High Molecular Weight RNA on Wide Pore SEC Column | Size ExclusionSRTRNA Separation on Wide Pore ColumnHPLC2
| OD1001 | Separation of a Nucleotide mixture on HP-C18 | Reversed PhaseHP-C18Nucleotide Analysis@ResolutionHPLC@LCMS2
| PD1006 | DNA Separation on Zenix SEC-300 and Proteomix SAX | Size Exclusion@Ion ExchangeProteomix@ZenixResolution@Orthogonal MethodHPLC2
| PD1005 | Oligonucleotide Separation on Proteomix SAX | Ion ExchangeProteomixResolutionHPLC2
| PD1004 | RNA Separation on Proteomix WAX | Ion ExchangeProteomixResolutionHPLC2
| PD1003 | DNA Separation on Proteomix WAX | Ion ExchangeProteomixResolutionHPLC2
| PD1002 | Separation of Oligonucleotide and its degraded fragments on Proteomix SAX | Ion ExchangeProteomixResolutionHPLC2
| PD1001 | Separation of Oligonucleotide and its impurities by Non Porous vs. Porous | Ion ExchangeProteomixPore Size Selection@ResolutionHPLC2
| ZD1001 | Oligonucleotides Analysis using Zenix-C SEC-100 | Size ExclusionZenix-CASO, siRNA, ssRNAHPLC2
| PD1012 | Oligonucleotides Analysis using SAX and RP | Ion ExchangeProteomixReversed Phase & Ion ExchangeHPLC2
| LR2023121487 | Literature Reference: Circular mRNA-based TCR-T Offers a Safe and Effective Therapeutic Strategy for Treatment of Cytomegalovirus Infection | SECSRTCircular mRNA-basedHPLC2